Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2008

Strategic Diagnostics Inks Deal to Develop Test to Predict Prostate Cancer Spread

  • Strategic Diagnostics (SDI), University of Delaware, and the Helen F. Graham Cancer Center are coming together to develop assays to detect prostate cancer metastasis. SDI will leverage the center’s Genomic Antibody Technology™ during this project for biomarker discover.

    The group will work to develop antibodies that detect the protein fragments left by cancer cells when they spread. They anticipate that a test using these antibodies will help determine the stage and severity of the cancer.

    Cancer cells implanted in normal tissue of the body cause damage to surrounding proteins upon breaking away from the primary tumor, leaving behind protein molecule fragments, according to the collaborators. These fragments are indicators that the cancer has metastasized.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »